Oh, What A Tangled Web We Weave When The CDC Decieves |“You are a pathetic liar”: CDC senior scientist to CDC’s head of immunization (DOCUMENT) | Sharyl Attkisson
Sharyl Attkisson, the epitome of girl power, is a fantastic journalist. It is no wonder the Obama administration hacked into her computer. So what is the real story when it comes to vaccines and the CDC: lies and coverups that do not allow parents to make good, informed decisions.
The real problem with movies like “Vaxxed” and journalists’ articles on the CDC that actually do straight investigative reporting is the CDC does not come out looking very good. It follows, according to the Corporate and Political Establishment, that these movies must be banned and these journalists must be stopped.
Get it?
“According to Thompson, he and his fellow CDC scientists covered up a link between MMR vaccine and autism in African-American boys. “The omitted data suggested that African American males who received the MMR vaccine before age 36 months were at increased risk for autism,” Thompson later testified.
Dr. William Thompson, PhD
CDC officials disposed of study documents “in a huge garbage can”
As part of the alleged fraud and coverup, Thompson said he and the other CDC scientists who conducted the research got together and literally trashed study data.
Thompson first revealed his role in the fraud during a series of phone conversations with the parent of an autistic child. The parent surreptitiously recorded the calls, in which Thompson confessed and said he lived with tremendous guilt.”
BREAKING: Reports are coming from Maricopa County, Arizona that Dominion voting machines are malfunctioning county-wide as a result of the CrowdStrike outage. Officials have long claimed that the machines are NEVER connected to the internet… you can laugh at those claims now… pic.twitter.com/t5A6SIImKY
Today’s verdict represents the culmination of a legal process that has been bent to the political will of the actors involved: a leftist prosecutor, a partisan judge and a jury reflective of one of the most liberal enclaves in America—all in an effort to “get” Donald Trump.
At Starbase, @ElonMusk provided an update on the company’s plans to send humanity to Mars, the best destination to begin making life multiplanetary pic.twitter.com/PiX8XOgQs5
Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., +24, and Luis A. Diaz, Jr., M.D.
BACKGROUND
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.
METHODS
We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
RESULTS
A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.
CONCLUSIONS
Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.
According to the results of a recent study, researchers have found a treatment that completely removed the rectal cancer in every patient that participated. Meaning that every single patient in the study is in remission—and with no chemotherapy, no radiation, and no surgery.
Even though the study was small, the results are not only heartening, but also, according to the lead researcher, they open up a potential new corridor at fighting cancer, which they will be expanding quickly to stomach, pancreatic, and bladder cancer.
Furthermore, the therapy that they’re testing (monoclonal antibodies) has none of the toxic side-effects of the other treatments for cancer that are currently used at scale.
And so, with all these positive elements lining up, let’s go through this study together.
For those who can’t spend 4 hours watching the full roundtable event – Federal Health Agencies and the COVID Cartel: What Are They Hiding – here is a 14-minute edited version that captures many important points. pic.twitter.com/YLpYaLp5gT
Last month U.S. District Judge Amy Totenberg ruled that a lawsuit against Georgia’s use of electronic voting machines must go to a non-jury trial in January. She ordered Secretary of State Brad Raffensperger to defend the state’s utilization of electronic voting prior to the upcoming presidential primary election because the lawsuit questions whether Georgia’s current system of computerized voting is safe or whether it is vulnerable to potential hacking.
However, the state (spending taxpayer money) is now appealing to the 11th Circuit Court of Appeals to keep Raffensperger from testifying.
Says one lawyer to James Magazine Online familiar with the case: “Raffensperger selected the system, repeatedly defends the system as secure, but now can’t take an hour or so in federal court to defend it.”
2:46 Alex Jones predictions
15:07 Deplatforming
21:59 Dividing us on race
25:37 The border
28:09 Austin
32:12 New World Order
42:09 Brian Stelter demon video
50:57 Depopulation
1:07:51 Food
1:13:51 Whiskey
1:16:22 Presidential… pic.twitter.com/IsJAQDUzDc
Wow…
Vivek Ramaswamy just went absolute savage mode on the RNC, calling out Ronna by name, and then NBC, flipping the moderator question back onto the moderator. Has this ever been done? pic.twitter.com/Hmdo7o5oY5
REPORT: Donald Trump reportedly pulled out a piece of paper from his suit jacket in court, claiming it would clear him of all wrongdoing in the $250M fraud case.
Left-wing Judge Arthur Engoron refused to let him read it.
Epic exchange between @benshapiro and an anti-Israel activist at Oxford University today. This “highly educated” student doesn’t know basic history pic.twitter.com/vbpfDnetgu
@RandPaul’s new book, “Deception: The Great Covid Cover-Up,” charges Anthony Fauci and others with funding dangerous research in China, and then covering it up. pic.twitter.com/1c6elBFCwP
